Search Follow us

 

PDL reported Q218 revenues of $46.6m, with Noden product revenue of $25.9m (up 45.1% compared to Q118). Almost all of that growth came from increased sales in Asia thanks to the launch in Japan by distribution partner Orphan Pacific. Noden product revenue in the US was down slightly (1%) in the quarter compared to Q118, and the future of Tekturna in the US is now in question following a settlement agreement with Anchen Pharmaceuticals, which would allow it to enter with a generic in the US after March 1, 2019. Subsequently, the company reported a $152.3m impairment of its Noden intangible asset with the estimated fair value now at $40.1m.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs